Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 12

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 12
---
 30, 2025.

Strategic Growth Plan

• Accelerate profitable revenue growth : We continue to focus on accelerating growth profitably over the long term. Over the past two years, our revenue has increased at a compound annual growth rate of 11.1% while we achieved positive adjusted EPS in fiscal year 2024. To drive continued growth, we plan to accelerate electronic medical records (EMR) integrations, expand our sales channels, including into large health systems, cross sell our portfolio of testing products to providers, enhance our testing products within medical guidelines, demonstrate our clinical differentiation and value compared to the standard of care, and optimize our revenue cycle processes.

• Ongoing development and commercialization of differentiated molecular diagnostic tests : We recently entered into a strategic collaboration with PATHOMIQ to add artificial intelligence (AI) technology to our Oncology portfolio including an exclusive license of PATHOMIQ AI technology platform for prostate cancer. We expect to commercially launch our first AI-driven prostate cancer clinical test in 2025. We are also excited about the potential contribution from recent product launches, including Prequel with 8-week Gestational Age, Foresight Universal Plus, and the continuing traction with our Precise Tumor comprehensive genomic panel. We also continue to invest in clinical evidence development to support the growth of our existing products and launch of new molecular testing products, including FirstGene, Precise Liquid, and Precise MRD, which is already available for research use by our pharmaceutical partners.

• Leverage technology and partnerships: We continue to advance our digital capabilities to enhance the end-to-end customer experience and drive increased sample volume. This includes automated patient identification and screening solutions for healthcare systems, such as the Breast Cancer Risk Assessment Program and AI-enhanced patient intake workflows. Additionally, we are leveraging external technologies and partnerships to expand and accelerate our offerings. In 2024, we transitioned our Intermountain partnership to an in-house capability, integrating Intermountain Healthcare’s genomics for tumor testing. Our collaboration with PATHOMIQ in prostate cancer will apply cutting-edge molecular diagnostics and high-performance AI to improve patient outcomes.

For additional information about our 2024 business performance, please see the CEO Letter above and the "Executive and Director Compensation-Compensation Discussion and Analysis-Fiscal Year 2024 Financial Highlights" section starting on page 30.

3

#### Corporate Governance Highligh

#### ts

#### (page 11)
.

| Strong Governance Practices                                                          |     |                                                                                                                   |     |                                                                                               |
| •Rob